#United States #Washington #Duchenne #PPMD #FED

Celebrating Advocacy in Duchenne Muscular Dystrophy

On March 9, 2026, a momentous event took place in Washington, D.C. The Parent Project Muscular Dystrophy (PPMD) in collaboration with the Foundation to Eradicate Duchenne (FED) presented the prestigious Advocacy Leadership Awards. This year, the awards highlighted the significant contributions of bipartisan leaders who are committed to promoting policies that accelerate research and improve care for individuals dealing with Duchenne and Becker muscular dystrophies.

Honoring Congressional Champions

The recipients of the 2026 Advocacy Leadership Awards included Representative Troy Balderson from Ohio, Senator Susan Collins from Maine, Senator Amy Klobuchar from Minnesota, Representative Doris Matsui from California, and Senator Roger Wicker from Mississippi. These individuals have showcased an admirable dedication to elevating the focus on federal policies that not only foster research but also enhance care infrastructures and provide access to transformative therapies for patients.

The ceremony coincided with the 25th anniversary of the Muscular Dystrophy Community Assistance, Research, and Education (MD-CARE) Act, a landmark legislation that has served as a cornerstone for muscular dystrophy advocacy since its enactment in 2001. This act has enabled the establishment of a coordinated federal framework facilitating research, care, and therapeutic development aimed at addressing muscular dystrophies like Duchenne.

The Power of Bipartisan Advocacy

“Bipartisan advocacy is crucial in driving impactful progress for the Duchenne and Becker community,” commented Lauren Stanford, PPMD’s Senior Director of Advocacy. She emphasized that this year’s honorees represent a collective commitment to ensuring that legislative efforts translate into tangible outcomes for families affected by these conditions.

Joel Wood, President of the FED, echoed this sentiment, highlighting the collaborative efforts between science, advocacy, and policy as key to achieving advancements in treatments and care standards. The combined efforts of the PPMD and FED underscore a shared goal: enhancing the quality of life for every individual impacted by Duchenne.

Looking Ahead: A Commitment to Innovation

The 2026 Advocacy Leadership Awards not only celebrate past achievements but also set the tone for future endeavors. PPMD and FED are resolute in their mission to advocate for innovative policies that promote research and improve access to care for Duchenne and Becker muscular dystrophy patients.

Over the past 25 years, the MD-CARE Act has played a pivotal role in facilitating groundbreaking discoveries in treatments and therapeutic options that alleviate the challenges faced by patients and their families. The advocacy leaders recognized this year exemplify what can be accomplished with dedication and partnership between lawmakers and the muscular dystrophy community.

As PPMD continues to push forward, it's clear that the results of these sustained advocacy efforts will not just benefit the present community but will also pave the way for future generations living with Duchenne.

About PPMD and FED

Parent Project Muscular Dystrophy is dedicated to fighting Duchenne muscular dystrophy through advocacy, research funding, and support for families affected by the condition. PPMD ensures optimal care and access to advancements to improve the lives of those impacted by Duchenne.

The Foundation to Eradicate Duchenne focuses on scientific research and essential advocacy efforts targeted towards effective therapies for young men suffering from this daunting disease.

For more information, visit PPMD or follow them on social media.